Literature DB >> 7681729

Microglia present myelin antigens to T cells after phagocytosis of oligodendrocytes.

E Cash1, Y Zhang, O Rott.   

Abstract

Cells that are capable of initiating immune reactions in the central nervous system (CNS) seem to be microglia, since they are the predominant CNS cell type expressing major histocompatibility complex (MHC) class II molecules. However, the capacity of microglia to induce myelin antigen-specific T lymphocyte activation is not yet well defined. With a coculture system allowing phagocytosis by microglia of progenitor or mature oligodendrocytes (synthesizing myelin basic protein, MBP), we show the ability of phagocytosis-activated microglia to express MHC class II antigen and to strongly induce T cell proliferation. The T cell proliferation was either mitogen mediated or antigen specific (MBP). Activation of microglia by phagocytosis may represent a major step in initializing immune responses in the CNS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681729     DOI: 10.1006/cimm.1993.1053

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

Review 1.  Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity.

Authors:  Ari Waisman; Lisa Johann
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

2.  Aberrant ER Stress Induced Neuronal-IFNβ Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI.

Authors:  Tanusree Sen; Pampa Saha; Rajaneesh Gupta; Lesley M Foley; Tong Jiang; Olena S Abakumova; T Kevin Hitchens; Nilkantha Sen
Journal:  J Neurosci       Date:  2019-11-06       Impact factor: 6.167

Review 3.  Do not judge a cell by its cover--diversity of CNS resident, adjoining and infiltrating myeloid cells in inflammation.

Authors:  Stefanie M Brendecke; Marco Prinz
Journal:  Semin Immunopathol       Date:  2015-08-07       Impact factor: 9.623

4.  Transforming growth factor-beta 1 (TGF-beta1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-gamma (IFN-gamma).

Authors:  B G Xiao; G X Zhang; C G Ma; H Link
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

5.  Microglial cells qualify as the stimulators of unprimed CD4+ and CD8+ T lymphocytes in the central nervous system.

Authors:  E Cash; O Rott
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 6.  Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis.

Authors:  Monica J Carson
Journal:  Glia       Date:  2002-11       Impact factor: 8.073

7.  Ciliary neurotrophic factor (CNTF) plus soluble CNTF receptor alpha increases cyclooxygenase-2 expression, PGE2 release and interferon-gamma-induced CD40 in murine microglia.

Authors:  Hsiao-Wen Lin; Mohit Raja Jain; Hong Li; Steven W Levison
Journal:  J Neuroinflammation       Date:  2009-03-06       Impact factor: 8.322

Review 8.  Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis.

Authors:  Gillian Margaret Tannahill; Nunzio Iraci; Edoardo Gaude; Christian Frezza; Stefano Pluchino
Journal:  Front Immunol       Date:  2015-03-11       Impact factor: 7.561

Review 9.  The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases.

Authors:  Diego Clemente; María Cristina Ortega; Carolina Melero-Jerez; Fernando de Castro
Journal:  Front Cell Neurosci       Date:  2013-12-20       Impact factor: 5.505

10.  M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination.

Authors:  Robin J M Franklin; Charles Ffrench-Constant; Veronique E Miron; Amanda Boyd; Jing-Wei Zhao; Tracy J Yuen; Julia M Ruckh; Jennifer L Shadrach; Peter van Wijngaarden; Amy J Wagers; Anna Williams
Journal:  Nat Neurosci       Date:  2013-07-21       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.